NCT05070247 2026-01-22
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Takeda
Phase 1/2 Terminated
Clinical Trials
48 trialsNCT04573881 2026-01-12
#HOPE4LIVER
HistoSonics, Inc.
Phase NA Active not recruiting
NCT04572633 2025-11-19
#HOPE4LIVER US
HistoSonics, Inc.
Phase NA Active not recruiting
NCT04696055 2025-05-13
Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors
Bayer
Phase 2 Completed
NCT05233098 2025-03-06
TheraSphere Post-Approval Study to Calculate the Radiation-absorbed Dose of Tc-99m MAA.
Boston Scientific Corporation
Completed
NCT03058289 2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2 Completed
NCT05848947 2025-01-29
MAApping
Sirtex Medical
Phase 4 Completed
NCT04340193 2024-11-26
CheckMate 74W
Bristol-Myers Squibb
Phase 3 Completed
NCT02112656 2024-08-20
OPTIMA
Imunon
Phase 3 Completed
NCT03586050 2024-07-24
Study to Evaluate the Safety and Effectiveness of Microwave Ablation in Patients With Hepatocellular Carcinoma in Korea
Ethicon, Inc.
Phase NA Completed
NCT03685591 2024-06-26
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
Pfizer
Phase 1 Terminated
NCT00617981 2024-05-03
Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)
Imunon
Phase 3 Completed
NCT05061537 2024-04-12
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
Pfizer
Phase 1 Terminated
NCT03753789 2024-01-05
Ablation Confirmation Study
Ethicon, Inc.
Phase NA Terminated
NCT03230318 2023-12-19
FIDES-01
Basilea Pharmaceutica
Phase 2 Completed
NCT02834780 2023-11-13
Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma
Eisai Inc.
Phase 1 Completed
NCT02795429 2023-07-03
Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC
Novartis
Phase 1/2 Completed
NCT01752920 2023-06-05
Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations
Basilea Pharmaceutica
Phase 1/2 Completed
NCT02435433 2023-01-20
REACH-2
Eli Lilly and Company
Phase 3 Completed
NCT01464593 2022-10-13
ABLATE
Imunon
Phase 2 Terminated
NCT01402908 2022-06-23
PATRON
Cellxpert Biotechnology Corp.
Phase 3 Terminated
NCT02315066 2022-04-21
Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
Pfizer
Phase 1 Completed
NCT01908426 2021-05-06
CELESTIAL
Exelixis
Phase 3 Completed
NCT01033240 2021-04-08
CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer
Daiichi Sankyo
Phase 2 Completed
NCT01636284 2021-01-20
FLASH
SillaJen, Inc.
Phase 2 Completed
NCT02082210 2020-12-19
A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1/2 Completed
NCT00503867 2020-12-10
SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma
Sirtex Medical
Phase NA Terminated
NCT01498952 2019-02-19
MEDI-573-1028
MedImmune LLC
Phase 1 Completed
NCT00692770 2018-08-08
STORM
Bayer
Phase 3 Completed
NCT00829413 2018-08-03
SonoVue®-Enhanced Ultrasound (US) Versus Unenhanced US for Focal Liver Lesion Characterization
Bracco Diagnostics, Inc
Phase 3 Completed
NCT00149396 2018-04-24
Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver
MediGene
Phase 1/2 Completed
NCT00788697 2017-12-12
SonoVue®-Enhanced Ultrasound Versus Unenhanced US for Focal Liver Lesion Characterization
Bracco Diagnostics, Inc
Phase 3 Completed
NCT01668017 2017-08-23
A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy
Merck KGaA, Darmstadt, Germany
Phase 1 Terminated
NCT01043523 2016-11-28
Liver MRI With Primovist/Eovist in Pediatric Subjects Who Are Suspected or Have Focal Liver Lesions.
Bayer
Completed
NCT01171924 2016-03-01
A Phase Ib Expansion Study Investigating the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced Head and Neck, Gastric, Breast, Liver and Non-small Cell Lung Cancer Tumors
Curis, Inc.
Phase 1 Completed
NCT00554372 2016-02-04
A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma
SillaJen, Inc.
Phase 2 Completed
NCT01232296 2015-12-04
A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment
Novartis
Phase 2 Completed
NCT00440310 2015-08-25
Phase 3 Trial of Litx™ Plus Chemotherapy vs. Chemotherapy Only Treating Colorectal Cancer Patients With Recurrent Liver Metastases
Light Sciences Oncology
Phase 3 Completed
NCT00105443 2014-10-31
SHARP
Bayer
Phase 3 Completed
NCT00108953 2014-10-31
A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma
Bayer
Phase 2 Completed
NCT00627042 2014-10-08
Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy
Eli Lilly and Company
Phase 2 Completed
NCT00576199 2014-08-29
A Study of Avastin (Bevacizumab) and Transarterial Chemoembolisation (TACE) Treatment in Patients With Liver Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT00605722 2014-07-14
A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer.
Hoffmann-La Roche
Phase 2 Completed
NCT02013830 2014-06-06
A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) in Patients With Advanced or Metastatic Liver Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT00044512 2014-04-16
A Study to Estimate Safety and Efficacy of Sorafenib (BAY43-9006) in the Treatment of Hepatocellular Carcinoma
Bayer
Phase 2 Completed
NCT00494299 2013-12-20
Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)
Bayer
Phase 3 Completed
NCT00143403 2010-09-28
Comparing Irinotecan and 5 FU/FA To 5-FU/FA After Resection Of Liver Metastases For Colorectal Cancer
Pfizer
Phase 3 Completed
NCT00247676 2010-02-18
An International Phase 2 Study Of SU011248 In Patients With Inoperable Liver Cancer
Pfizer
Phase 2 Completed